Kopp Investment Advisors LLC decreased its holdings in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 5.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 105,126 shares of the biopharmaceutical company’s stock after selling 6,389 shares during the quarter. Horizon Pharma comprises about 1.5% of Kopp Investment Advisors LLC’s investment portfolio, making the stock its 25th largest position. Kopp Investment Advisors LLC’s holdings in Horizon Pharma were worth $1,535,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Advantage Investment Management LLC raised its stake in Horizon Pharma by 164.8% during the third quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,900 shares in the last quarter. BlueCrest Capital Management Ltd bought a new position in Horizon Pharma during the fourth quarter valued at $160,000. K2 Principal Fund L.P. increased its position in Horizon Pharma by 126.1% during the fourth quarter. K2 Principal Fund L.P. now owns 11,074 shares of the biopharmaceutical company’s stock valued at $162,000 after acquiring an additional 53,574 shares during the last quarter. Brown Advisory Inc. bought a new position in Horizon Pharma during the third quarter valued at $145,000. Finally, Investors Research Corp bought a new position in Horizon Pharma during the fourth quarter valued at $174,000. 86.77% of the stock is currently owned by institutional investors.
Horizon Pharma PLC (HZNP) opened at $15.73 on Monday. The company has a quick ratio of 1.54, a current ratio of 1.63 and a debt-to-equity ratio of 1.91. The company has a market cap of $2,588.69, a PE ratio of -6.24, a PEG ratio of 0.67 and a beta of 1.34. Horizon Pharma PLC has a 1-year low of $9.45 and a 1-year high of $16.02.
A number of research analysts have weighed in on HZNP shares. Cowen reiterated a “buy” rating and set a $24.00 price objective on shares of Horizon Pharma in a research report on Thursday, March 1st. UBS Group set a $20.00 price objective on shares of Horizon Pharma and gave the company a “buy” rating in a research report on Thursday, March 1st. Cantor Fitzgerald set a $17.00 price objective on shares of Horizon Pharma and gave the company a “buy” rating in a research report on Wednesday, February 28th. BidaskClub upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. Finally, Mizuho upgraded shares of Horizon Pharma from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $12.00 to $18.00 in a research report on Friday, January 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Horizon Pharma has a consensus rating of “Buy” and an average price target of $18.64.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2018/03/12/kopp-investment-advisors-llc-sells-6389-shares-of-horizon-pharma-plc-hznp.html.
Horizon Pharma Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.